Comparison of the broth microdilution methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for testing itraconazole, posaconazole, and voriconazole against Aspergillus isolates

Journal of Clinical Microbiology

Volumn 49, Issue 3, 2011, Pages 1110-1112

  Pfaller, M ^a   Boyken, L ^a   Hollis, R ^a   Kroeger, J ^a   Messer, S ^a   Tendolkar, S ^a   Diekema, D ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS GLAUCUS; ASPERGILLUS NIDULANS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; ASPERGILLUS VERSICOLOR; BROTH DILUTION; CONTROLLED STUDY; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; ASPERGILLUS; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES;

ASPERGILLUS;

EID: 79952320388     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02432-10     Document Type: Article

References (29)

1. Baddley, J. W., et al. 2009. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J. Clin. Microbiol. 47:3271-3275.
2. Chen, A., and J. D. Sobel. 2005. Emerging azole antifungals. Expert Opin. Emerg. Drugs 10:21-33.
3. Chryssanthou, E., and M. Cuenca-Estrella. 2002. Comparison of the Anti-fungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing Proposed Standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J. Clin. Microbiol. 40:3841-3844.
4. Chryssanthou, E., and M. Cuenca-Estrella. 2006. Comparison of the EUCAST-AFST broth dilution method with the CLSI reference broth dilution method (M38-A) for susceptibility testing of posaconazole and voriconazole against Aspergillus spp. Clin. Microbiol. Infect. 12:901-904. (Pubitemid 44151291)
5. nd ed. M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Cuenca-Estrella, M., et al. 2002. Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of Candida species. Antimicrob. Agents Chemother. 46:3644-3647. (Pubitemid 35192943)
7. Cuenca-Estrella, M., et al. 2007. Multicenter determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin. Microbiol. Infect. 13:1018-1022.
8. Espinel-Ingroff, A., et al. 2005. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J. Clin. Microbiol. 43:3884-3889.
9. Espinel-Ingroff, A., et al. 2010. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J. Clin. Microbiol. 48:3251-3257.
10. Gomez-Lopez, A., et al. 2003. In vitro activities of three licensed antifungal agents against Spanish clinical isolates of Aspergillus spp. Antimicrob. Agents Chemother. 47:3085-3088. (Pubitemid 37229561)
11. Howard, S. J., et al. 2009. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15:1068-1076.
12. Lass-Flörl, C. 2009. Azole resistance in aspergillosis: the next threat? Curr. Fungal Infect. Rep. 3:236-242.
13. Lass-Florl, C., M. Cuenca-Estrella, D. Denning, and J. Rodriguez-Tudela. 2006. Antifungal susceptibility testing in Aspergillus spp. according to EUCAST methodology. Med. Mycol. 44(Suppl. 1):319-325.
14. Lass-Flörl, C., A. Alastruey-Izquierdo, M. Cuenca-Estrella, S. Perkhofer, and J. L. Rodriguez-Tudela. 2009. In vitro activities of various antifungal drugs against Aspergillus terreus: global assessment using the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents Chemother. 53:794-795.
15. Lass-Florl, C., S. Perkhofer, and A. Mayr. 2010. In vitro susceptibility testing in fungi: a global perspective on a variety of methods. Mycoses 53:1-11.
16. Pfaller, M. A., et al. 2008. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J. Clin. Microbiol. 46:2568-2572.
17. Pfaller, M. A., et al. 2009. Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J. Clin. Microbiol. 47:3142-3146.
18. Pfaller, M. A., et al. 2009. In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method. J. Clin. Microbiol. 47:3323-3325.
19. Pfaller, M., et al. 1 December 2010. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles. J. Clin. Microbiol. doi:10.1128/JCM.02136-10.
20. Pfaller, M. A., et al. 12 January 2011. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) with the 24-h CLSI BMD method for fluconazole, posaconazole, and voriconazole susceptibility testing of Candida species using epidemiological cutoff values. J. Clin. Microbiol. doi:10.1128/JCM.02441-10.
21. Rodriguez-Tudela, J. D., et al. 2007. Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E. Dis.7.1) and CLSI (M27-A2). J. Clin. Microbiol. 45:109-111.
22. Rodriguez-Tudela, J. L., et al. 2008. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 52:2468-2472. (Pubitemid 351915677)
23. Snelders, E., et al. 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PloS Med. 5:e219.
24. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). 2008. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin. Microbiol. Infect. 14:982-984.
25. van der Linden, J. W. M., et al. 2009. Azole-resistant central nervous system aspergillosis. Clin. Infect. Dis. 448:1111-1113.
26. Verweij, P. E., and M. E. Brandt. 2007. Aspergillus, Fusarium, and other opportunistic moniliaceous fungi, p. 1802-1838. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. L. Landry, and M. A. Pfaller (ed.), Manual of clinical microbiology, 9th ed. ASM Press, Washington, DC.
27. Verweij, P. E., E. Mellado, and W. J. G. Melchers. 2007. Multiple-triazole-resistant aspergillosis. N. Engl. J. Med. 356:1481-1483.
28. Verweij, P. E., S. J. Howard, W. J. G. Melchers, and D. W. Denning. 2009. Azole resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist. Updat. 12:141-147.
29. Walsh, T. J., et al. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.